Waterview Plaza
Suite 310 2001 Route 46
Parsippany, NJ 07054
United States
855 776 6419
https://www.interpace.com
Settore/i: Healthcare
Settore: Diagnostics & Research
Impiegati a tempo pieno: 108
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Thomas W. Burnell Ph.D. | President, CEO & Chairman | 634,17k | N/D | 1963 |
Mr. Christopher McCarthy | Chief Financial Officer | N/D | N/D | 1992 |
Dr. Sydney D. Finkelstein | Chief Scientific Officer | N/D | N/D | N/D |
Mr. Jody Campbell | Chief Revenue Officer | N/D | N/D | N/D |
Dr. Nicole Massoll M.D. | Chief Medical Officer | N/D | N/D | N/D |
Mr. Patrick Kane | VP & Corporate Controller | N/D | N/D | N/D |
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis and prognosis of pancreatic cancer; PanDNA, a molecular only version of PancraGEN; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company primarily serves physicians, cancer center, clinics, laboratories, pathology groups, and hospitals. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
L'ISS Governance QualityScore di Interpace Biosciences, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.